• Citer

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

par Shi, W;Jiang, T;Nuciforo, Paolo;Hatzis, Christos;Holmes, E;Harbeck, Nadia;Sotiriou, Christos ;Peña, L;Loi, Sherene ;Rosa, D D;Chia, S;Wardley, Andrew;Ueno, T;Rossari, José ;Eidtmann, H;Armour, A;Piccart-Gebhart, Martine ;Rimm, David D.L.;Baselga, José;Pusztai, Lajos
Référence Annals of oncology, 28(1), page (128-135)
Publication Publié, 2017-01-01

Article révisé par les pairs

• Détails
• Contenu

Résumé :

We performed whole-exome sequencing of pretreatment biopsies and examined whether genome-wide metrics of overall mutational load, clonal heterogeneity or alterations at variant, gene, and pathway levels are associated with treatment response and survival.